Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 15/20 | 0.54 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25883240 | 0.79 | MALT1 (0.59) | MALT1TAS2R14CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15881106 | 0.76 | MALT1 (0.59) | MALT1TAS2R14CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL17117515 | 0.76 | MALT1 (0.59) | MALT1TAS2R14CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL29162073 | 0.74 | MALT1 (0.57) | MALT1TAS2R14CYP3A4CYP2C19 | |
| SCHEMBL20428021 | 0.74 | MALT1 (0.57) | MALT1TAS2R14 | |
| SCHEMBL25083859 | 0.71 | MALT1 (0.54) | MALT1TAS2R14 | |
| SCHEMBL8177865 | 0.71 | MALT1 (0.54) | MALT1TAS2R14CYP2C9CYP2C19 | |
| SCHEMBL28338196 | 0.69 | SCN9A (0.53) | MALT1 | |
| SCHEMBL29340359 | 0.69 | MALT1 (0.51) | MALT1CYP3A4 | |
| SCHEMBL28137210 | 0.69 | MALT1 (0.51) | MALT1TAS2R14CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | MALT1 4719/4885TAS2R14 2430/4885CYP3A4 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.